Post-COVID-19 Chronic Fatigue Syndrome

ClinAmygate

Status and phase: Completed; Phase 4

Conditions: Post-COVID Syndrome; Post-COVID-19 Syndrome

Treatments: Drug: Synthetic Vitamin B1

Study type: Interventional

Funder types: Other

Identifiers

NCT05642923

PR0012022

Details and patient eligibility

About

Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

Full description

It has become increasingly clear that infected patients have symptoms not only in the acute phase, but also after recovery from the initial infection.

A recent meta-analysis including 4828 patients with post-COVID-19 showed that symptoms and post-acute sequelae of SARS-CoV-2 can persist weeks to months after the infection.

These patients who reported persistent symptoms have been termed "long haulers" or described as having long COVID, post-acute COVID-19, persistent COVID-19 symptoms, post COVID-19 manifestations, long-term COVID-19 effects, post-acute sequelae of COVID-19 (PASC), or post-COVID-19 syndrome.

Enrollment: 528 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age . 18
• Male or female
• Post-Covid-19 Fatigue

Exclusion criteria

• refusal

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

528 participants in 2 patient groups

Synthetic Vitamin B1

Active Comparator group

Description:

Synthetic Vitamin B1, 400 mg per day

Treatment:

Drug: Synthetic Vitamin B1

No intervention

No Intervention group

Description:

No intervention